Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma

Additional locations may be listed on ClinicalTrials.gov for NCT00636168.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationBristol-Myers Squibb

Principal Investigatorunknown unknown

• Primary IDCA184-029
• Secondary IDsNCI-2009-01391, EORTC 18071
• ClinicalTrials.gov IDNCT00636168